CN1562111A - Use of cassia sophera stem and leaf extract in preparing medicine for treating diabetes and improving its symptom - Google Patents
Use of cassia sophera stem and leaf extract in preparing medicine for treating diabetes and improving its symptom Download PDFInfo
- Publication number
- CN1562111A CN1562111A CN 200410010732 CN200410010732A CN1562111A CN 1562111 A CN1562111 A CN 1562111A CN 200410010732 CN200410010732 CN 200410010732 CN 200410010732 A CN200410010732 A CN 200410010732A CN 1562111 A CN1562111 A CN 1562111A
- Authority
- CN
- China
- Prior art keywords
- group
- stem
- cassia sophera
- leaf extract
- leaf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
An application of the inflated fruit senna stem and leaf's extract in preparing the medicine for treating diabetes and decreasing blood sugar is disclosed.
Description
Technical field
The invention belongs to the medicinal usage field of Chinese medicine.
Background technology
Cassia sophera Linn (Cassia sophera Linn.), medicinal plants, pulse family Caesalpinoidea Cassia.According to putting down in writing in " Chinese medicine voluminous dictionary ": " Cassia sophera Linn claims the Cassia sophera Linn Semen Cassiae again, and property is flat, and is nontoxic, and sweet in the mouth is sliding.Have expectorant and quench the thirst, make us sitting up, the effect in the accent.Be called antipyretic again.The ethanol extract of Cassia sophera Linn leaf has the effect of lax small intestine of guinea pig, bronchial smooth muscle." be the extract that refers to the Cassia sophera Linn stem and leaf among the present invention.
Summary of the invention
Purpose of the present invention is exactly the medicine of using Cassia sophera Linn stem and leaf water extract preparation treatment diabetes and improving its symptom.
Its water extract adopts the water extracting method to be:
1. decocting method: with water is solvent, and the heated and boiled effective component extracting generally must extract 2～4 times, and the solvent consumption is generally 6～20 times of Cassia sophera Linn amount.
2. percolation: for the Cassia sophera Linn stem and leaf behind merceration bubble or warm macerating bubble, with the solvent of proper temperature, the Cassia sophera Linn stem and leaf of flowing through is with the composition of stripping Cassia sophera Linn stem and leaf.
3. infusion process: be a large amount of solvent mercerations bubbles or warm macerating bubble Cassia sophera Linn stem and leaf, treat composition stripping balance after, directly emit extracting solution.
4. ultrasonic extraction: for the Cassia sophera Linn stem and leaf after soaking, put in the ultrasound wave with solvent, utilize hyperacoustic effect, make the stripping of Cassia sophera Linn stem and leaf composition.
5. microwave extraction method: Cassia sophera Linn stem and leaf and solvent are together put in the microwave, utilized microwave to make molecular polarization, and make its composition stripping.
When the present invention was used to prepare the treatment diabetes and improves the medicine of its symptom, its oral or parenteral all was safe.Under oral situation, it can any conventionally form administration, as powder, granule, tablet, capsule, pill, solution, suspension, syrup, buccal tablets, sublingual lozenge etc.; When this medicine parenteral, can take any conventionally form, injection for example is as intravenous injection, ointment, suppository, percutaneous dosing, inhalant etc.
It is to be made of the excipient of Cassia sophera Linn stem and leaf water extract with solid or liquid that the present invention prepares the medicine for the treatment of diabetes and improving its symptom, the excipient of solid used herein or liquid is well known in the art, lift several object lessons below, powder is the powder agent that takes orally, its excipient has lactose, starch, dextrin, calcium carbonate, synthetic or puritan filler aluminum, magnesium oxide, magnesium stearate, sodium bicarbonate, dry yeast etc.; The excipient of solution has water, glycerol, propylene glycol, simple syrup, ethanol, ethylene glycol, Polyethylene Glycol, sorbitol etc.; The excipient of ointment can use fatty oil, and agnolin, vaseline, glycerol, Cera Flava, wood are cured, white oil, resin, senior water-repelling agent or the hydrophilizing agent that is combined into such as cured.
The dosage of active substance can be according to the mode of taking, and patient's age and body weight and the degree that is in a bad way change with other similar factor, and oral dose is: 10.0～50.0mg/kg, and every day, secondary was taken; Injection 8.0～30.0mg/kg, once a day.
Medicine of the present invention has blood sugar lowering preferably, treat diabetes and improve the effect of symptom.
The specific embodiment
Below further set forth the beneficial effect that application the present invention prepares described medicine by pharmacodynamics test example.
Test of the influence of routine Cassia sophera Linn stem and leaf extract to diabetes rat.
Experimental technique
With 60 normal Wistar rats, leave and take 10 as the normal control group; Fasting be can't help water after 16 hours, and lumbar injection streptozotocin 54mg/kg makes hyperglycemia model.After 10 days, survey fasting glucose, blood glucose value is that hyperglycemia model is set up greater than 11.1mmol/L, and the result has 50 rats becomes diabetes rat.The diabetes rat random packet is as follows: model group, positive drug group: diabetes pill group, the heavy dose of group of Cassia sophera Linn stem and leaf water extract 0.4g/kg/d, middle dosage group 0.2g/kg/d, small dose group 0.1g/kg/d, 10 every group.Every morning gastric infusion, the administration volume is 10ml/kg.Weigh, survey blood glucose weekly once, and by the new dosage of new body weight conversion.After around the administration, lumbar injection 2% pentobarbital sodium water solution 2.3ml/kg anaesthetizes, and from abdominal aortic blood, surveys blood parameters, routine blood test, clotting time, hemorheology index.
Experimental result
(1), to the influence of blood glucose in diabetic rats value
Successive administration is after three weeks, and Cassia sophera Linn stem and leaf extract heavy dose of group animal subject blood glucose value and model group animal subject blood glucose value relatively have difference P＜0.05 of obvious statistical significance.After around the administration, positive drug group, the big or middle dosage group of Cassia sophera Linn stem and leaf extract animal subject blood glucose value and model group relatively have the difference (P＜0.05) of obvious statistical significance.
Table 1 Cassia sophera Linn stem and leaf extract to the influence of hyperglycemia model rat blood sugar value (mmol/L) (x ± s, n=10)
Group administration last Wednesday Tuesday of Zhou Sizhou
Normal control group 5.44 ± 0.52 5.46 ± 0.70 4.91 ± 0.64 5.10 ± 0.86 5.26 ± 0.31
Model group 17.70 ± 2.61 17.58 ± 1.46 19.07 ± 2.17 19.37 ± 2.52 17.24 ± 2.91
Positive drug group 18.08 ± 2.90 18.97 ± 2.76 16.65 ± 3.00 17.17 ± 3.55 13.76 ± 3.06
*
Heavy dose of group 19.48 ± 3.42 19.17 ± 3.52 17.62 ± 2.22 16.43 ± 2.67
*13.63 ± 4.21
*
Middle dosage group 18.92 ± 3.64 18.41 ± 3.16 17.20 ± 2.84 16.68 ± 3.53 14.21 ± 3.44
*
Small dose group 17.28 ± 2.22 16.24 ± 2.31 17.47 ± 1.71 17.09 ± 2.69 14.86 ± 2.45
Compare with model group,
*P＜0.05.
(2), to the influence of diabetes rat body weight
Big or middle dosage group of Cassia sophera Linn stem and leaf extract and positive drug group compare the influence and the model group of the weight of animals, have the difference (P＜0.05) of obvious statistical significance, the results are shown in Table 2.
Table 2 Cassia sophera Linn stem and leaf extract to the influence of diabetes rat body weight (g) (x ± s, n=10)
Group administration last Wednesday Tuesday of Zhou Sizhou
Normal control group 198.3 ± 26.9 221.8 ± 38.9 240.4 ± 53.3 250.7 ± 59.9 268.1 ± 67.2
Model group 178.7 ± 23.9 173.8 ± 31.7 178.8 ± 49.5 165.5 ± 36.0 163.8 ± 36.0
Positive drug group 183.3 ± 20.3 186.4 ± 25.0 189.5 ± 26.9 193.6 ± 31.1 203.4 ± 37.3
*
Heavy dose of group 196.5 ± 17.9 187.2 ± 19.8 182.0 ± 22.0 181.8 ± 20.9 192.6 ± 21.2
*
Middle dosage group 202.4 ± 28.7 187.6 ± 21.2 181.3 ± 13.6 174.4 ± 23.2 193.2 ± 24.2
*
Small dose group 199.8 ± 30.7 193.1 ± 19.2 194.9 ± 16.1 194.0 ± 25.6 191.0 ± 29.7
Compare with model group,
*P＜0.05.
(3), to the influence of diabetes rat blood parameters
The blood glucose value and the model group of big or middle dosage group of Cassia sophera Linn stem and leaf extract and positive drug group more all have obvious decline, have statistical significance (P＜0.05).The results are shown in Table 3.
Table 3 Cassia sophera Linn stem and leaf extract to the influence of diabetes rat biochemical indicator (x ± s, n=10)
Group ALT (U/L) AST (U/L) TP (g/L) ALB (g/L) GLB (g/L)
Normal control group 62.2 ± 19.6 133.2 ± 51.2 66.3 ± 3.6 21.7 ± 1.2 44.5 ± 3.4
Model group 134.8 ± 69.1 272.4 ± 126.7 65.1 ± 7.6 16.6 ± 3.0 48.5 ± 8.1
Positive drug group 100.7 ± 36.9 188.2 ± 65.8 65.9 ± 6.4 17.1 ± 2.1 48.8 ± 7.2
Heavy dose of group 75.9 ± 66.5 255.0 ± 326.3 60.2 ± 7.7 19.6 ± 4.4 43.6 ± 7.3
Middle dosage group 85.0 ± 48.1 278.9 ± 59.2 60.7 ± 4.7 20.8 ± 6.3 41.2 ± 11.3
Small dose group 130.3 ± 63.4 426.6 ± 238.4 57.3 ± 15.3 19.6 ± 3.5 38.5 ± 15.4
Group TBIL (umol/L) ALP (U/L) GLU (mmol/L) CHO (mmol/L) CRE (umol/L)
Normal control group 5.1 ± 3.3 131.4 ± 57.1 8.1 ± 0.8 1.1 ± 0.2 67.4 ± 15.7
Model group 0.3 ± 2.4 471.2 ± 269.7 16.8 ± 6.3 0.9 ± 0.3 59.1 ± 11.9
Positive drug group 0.9 ± 0.9 371.3 ± 185.8 12.2 ± 2.9
*0.9 ± 0.2 60.0 ± 4.3
Heavy dose of group 2.4 ± 2.2 280.6 ± 172.7 11.1 ± 3.5
*1.3 ± 0.5 67.4 ± 5.4
Middle dosage group 2.1 ± 1.9 270.0 ± 177.9 10.6 ± 4.3
*1.2 ± 0.3 67.5 ± 6.2
Small dose group 2.7 ± 3.0 287.0 ± 88.2 21.9 ± 7.9 1.2 ± 0.4 63.1 ± 15.1
Compare with model group,
*P＜0.05.
(4), to the influence of diabetes rat routine blood test
Each administration group routine blood test and model group be not statistically significant (P＞0.05) relatively, the results are shown in Table 4.
Table 4 Cassia sophera Linn stem and leaf extract to the influence of diabetes rat routine blood test (x ± s, n=10)
Group WBC (G/L) LYM (%L) GRAN (%G) RBC (T/L) HGB (G/L) PLT (G/L)
Normal control group 7.2 ± 4.1 74.5 ± 6.1 12.7 ± 4.4 7.3 ± 0.4 135.2 ± 6.6 838.5 ± 116.3
Model group 10.0 ± 4.6 67.8 ± 8.8 18.5 ± 10.8 7.3 ± 0.7 130.7 ± 10.6 907.0 ± 161.4
Positive drug group 10.9 ± 5.5 64.6 ± 12.5 24.3 ± 14.5 7.1 ± 1.1 127.7 ± 20.3 843.7 ± 198.5
Heavy dose of group 6.9 ± 2.1 73.1 ± 2.8 20.2 ± 6.5 6.9 ± 1.1 137.7 ± 8.7 952.7 ± 149.5
Middle dosage group 6.8 ± 2.2 62.2 ± 16.5 31.7 ± 16.9 6.9 ± 0.4 137.9 ± 7.7 916.4 ± 220.1
Small dose group 7.0 ± 2.0 61.7 ± 15.7 30.1 ± 14.4 6.8 ± 1.1 137.1 ± 17.9 901.5 ± 230.4
(5), to the hemorheological influence of diabetes rat
Each administration group routine blood test and model group be not statistically significant (P＞0.05) relatively, the results are shown in Table 5.
Table 5 Cassia sophera Linn stem and leaf extract to the hemorheological influence of diabetes rat (x ± s, n=10)
Group packed cell volume % whole blood height is cut low specific viscosity plasma viscosity (mPa.s) the Fibrinogen % that cuts of specific viscosity whole blood
Normal control group 42.0 ± 1.6 6.3 ± 0.6 7.7 ± 0.6 1.5 ± 0.0 1.4 ± 0.4
Model group 42.0 ± 1.7 7.0 ± 1.0 8.4 ± 1.0 1.6 ± 0.1 2.1 ± 0.7
Positive drug group 44.4 ± 3.9 7.4 ± 0.4 9.0 ± 0.4 1.7 ± 0.2 2.8 ± 0.9
Heavy dose of group 41.1 ± 1.4 5.6 ± 1.8 7.2 ± 1.6 1.6 ± 0.1 1.6 ± 0.6
Middle dosage group 40.6 ± 3.3 5.5 ± 2.0 7.2 ± 1.6 1.6 ± 0.5 1.6 ± 0.4
Small dose group 39.7 ± 3.6 6.0 ± 1.9 7.2 ± 1.5 1.5 ± 0.1 1.5 ± 0.6
Experiment conclusion
The heavy dose of group of Cassia sophera Linn stem and leaf extract (0.4g/kg/d), middle dosage group (0.2g/kg/d) have the effect that reduces blood glucose in diabetic rats level due to the streptozotocin.And each administration group does not have obvious influence to other blood parameters of diabetes rat, routine blood test, hemorheology index.
Embodiment 1
Cassia sophera Linn stem and leaf water extract 2.0g, water 10000ml, in 100 bottles of packing into after the mixing, every 100ml contains Cassia sophera Linn stem and leaf extract 20mg.
Embodiment 2
Cassia sophera Linn stem and leaf 15.0g, medical starch 485g, the two fully mixes, and is encapsulated, makes 1000 capsules, and every heavy 0.5g contains Cassia sophera Linn stem and leaf extract 15mg.
Claims (1)
1, boundless and indistinct stem and leaf extract is in the treatment diabetes and improve application in its symptom medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410010732 CN1562111A (en) | 2004-03-19 | 2004-03-19 | Use of cassia sophera stem and leaf extract in preparing medicine for treating diabetes and improving its symptom |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410010732 CN1562111A (en) | 2004-03-19 | 2004-03-19 | Use of cassia sophera stem and leaf extract in preparing medicine for treating diabetes and improving its symptom |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1562111A true CN1562111A (en) | 2005-01-12 |
Family
ID=34477868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410010732 Pending CN1562111A (en) | 2004-03-19 | 2004-03-19 | Use of cassia sophera stem and leaf extract in preparing medicine for treating diabetes and improving its symptom |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1562111A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102422926A (en) * | 2011-11-09 | 2012-04-25 | 肖梅芬 | Cassia obtusifolia tea bag with functions of weight reduction, hypotension and hypoglycemic effect and its production process |
| CN102488045A (en) * | 2011-11-30 | 2012-06-13 | 肖梅芬 | Inflatedfruit senna seed electuary for losing weight and reducing pressure and sugar, and production process thereof |
| CN102524790A (en) * | 2012-03-19 | 2012-07-04 | 肖梅芬 | Medicine-food dual-purpose sugar-reducing series foods and preparation method thereof |
| CN102551065A (en) * | 2012-03-19 | 2012-07-11 | 肖梅芬 | Blood sugar reducing food series |
-
2004
- 2004-03-19 CN CN 200410010732 patent/CN1562111A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102422926A (en) * | 2011-11-09 | 2012-04-25 | 肖梅芬 | Cassia obtusifolia tea bag with functions of weight reduction, hypotension and hypoglycemic effect and its production process |
| CN102422926B (en) * | 2011-11-09 | 2013-04-17 | 肖梅芬 | Cassia obtusifolia tea bag with functions of weight reduction, hypotension and hypoglycemic effect and its production process |
| CN102488045A (en) * | 2011-11-30 | 2012-06-13 | 肖梅芬 | Inflatedfruit senna seed electuary for losing weight and reducing pressure and sugar, and production process thereof |
| CN102524790A (en) * | 2012-03-19 | 2012-07-04 | 肖梅芬 | Medicine-food dual-purpose sugar-reducing series foods and preparation method thereof |
| CN102551065A (en) * | 2012-03-19 | 2012-07-11 | 肖梅芬 | Blood sugar reducing food series |
| CN102524790B (en) * | 2012-03-19 | 2013-06-12 | 肖梅芬 | Medicine-food dual-purpose sugar-reducing series foods and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1250246C (en) | Medicinal mixture possessing alpha glycocidase inhibiting activity and its use | |
| CN1899322A (en) | Chinese medicine preparation with organism immunity increasing function | |
| CN1876074A (en) | A constipation-treating medicament and preparation method thereof | |
| CN1562111A (en) | Use of cassia sophera stem and leaf extract in preparing medicine for treating diabetes and improving its symptom | |
| CN1686377A (en) | Chuankezhi (pant treating) powder injection and its preparation method | |
| CN1179726C (en) | Application of naringin in preparing medicine for supporting treatment of SARS | |
| CN1698820A (en) | Dripping pills with jaundice eliminating liver protecting functions and its preparation method | |
| CN1903213A (en) | Traditional Chinese medicine preparation with functions of immunological regulation for anti-chemical damage | |
| CN1720948A (en) | Dripping pills of lllicium henryi dripping pills and method for preparing the same | |
| CN1139565A (en) | Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method | |
| CN1248698C (en) | Drug for treating coronary heart disease or coronary disease and cardiac insufficiency, and its preparation method | |
| CN101032534A (en) | Method of preparing jiubiying total saponins and the application thereof | |
| CN1548142A (en) | Medicine for improving sugar tolerance and treating diabetes and its prepn process | |
| CN1240709C (en) | Herminium's triochistisaponine extract and its extraction refining method and its medical use | |
| CN1843460A (en) | Medicine for reducing blood sugar, blood pressure and improving microcirculation and immunity, and its preparation method | |
| CN101053587A (en) | Medicinal composition for treating tumor and preparation method and quality control method thereof | |
| CN1513463A (en) | Application of timosaponin A3 for preparing medicine for treating No.2 type diabetes mellitus | |
| CN1771974A (en) | Application of hedgedog fungus mycelium oligose in preparing medicine | |
| CN1689579A (en) | Application of burdock glycoside or its aglycon in preparation of medicine for treating diabetes or its complications | |
| CN1772287A (en) | Application of hedgehog fungus mycelium glucoprotein in preparing medicine | |
| CN1524869A (en) | Method for extracting anticarcinogenesis polysaccharide composite AVDS from A.valvataD. and its use as medicament | |
| CN101036714A (en) | Medicinal composition for treating and/or preventing diabetes | |
| CN1682804A (en) | Oral administration dripping pill for nourishing heart to calm mind and its preparing method | |
| CN1762456A (en) | Medicine for improving female estrogen and immunity | |
| CN1262270C (en) | Application of levocarnitine and its derivative in preventing and treating high altitude diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |